Abstract Library

#2927 Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies

Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) have variable behaviour. Systemic chemotherapy (Chemo) is often extrapolated from colon cancer. KRAS mutations (KRAS-mut) are rare and more often present in Tang-C/high grade. The role of anti-EGFR antibodies (MoAb) is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Barriuso J, Martin A, Chakrabarty B, Burghel G, Lamarca A,

Keywords: goblet cell adenocarcinomas, chemotherapy, anti-egfr,

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, vascular endothelial growth factor Receptor 3, expression, clinical significance,